Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operated by ...

The Danish investment company Novo Nordisk A/S has received approval from the US Federal Trade Commission (FTC) to acquire the production assets of Catalent Inc., one of the world's largest ...

Moreover, free cash flow turned negative at minus DKK14.7 billion, largely due to heavy capital expenditures and the Catalent acquisition. Despite these challenges, Novo Nordisk remains well ...

Novo Nordisk also reported the acquisition of three manufacturing sites from Novo Holdings A/S following the finalization of Novo Holdings' acquisition of Catalent, Inc. - a global contract ...

In addition to the expansion in Denmark, Novo Nordisk will increase its exposure in countries such as Brazil, France, China and, of course, the United States. In addition, last year Catalent was ...

Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired ...

Novo Nordisk NVO shares have lost 21% in the past ... primarily driven by increased sales of Wegovy and Ozempic. The closing of the Catalent deal in December last year is also expected to help ...